- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05093998
Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza
Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza
Study Overview
Detailed Description
This study is an international, multicenter, double-blind, randomized, placebo-controlled, phase III clinical trial in parallel groups evaluating the efficacy and safety of AV5080 in patients with uncomplicated influenza.
Only patients with mild to moderate influenza, without complications, will be included in the study. Taking into account the seasonality of the pathology and the low percentage of influenza in the general structure of ARVI incidence, for the successful inclusion of all patients in the study during two epidemiological seasons. The study will enroll 700 patients aged 18 to 65 years with a confirmed clinical diagnosis of influenza to treatment (AV5080) and placebo cohorts (1:1).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Yulia Trakhtenberg, PhD
- Phone Number: +7 (495) 276-11-43
- Email: jat@ipharma.ru
Study Contact Backup
- Name: Xenia Kopylova
- Phone Number: +7 (495) 276-11-43
- Email: kka@ipharma.ru
Study Locations
-
-
-
Krasnodar, Russian Federation
- Specialized clinical Infectious diseases Hospital
-
Murmansk, Russian Federation
- Murmansk Regional Clinic named after P.A. Bayandin
-
Novosibirsk, Russian Federation
- Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
-
Saint Petersburg, Russian Federation
- Center for the Prevention and Control of AIDS and Infectious Diseases
-
Saint Petersburg, Russian Federation
- First Saint Petersburg State Medical University named after I.I. Academician Pavlov
-
Saint Petersburg, Russian Federation
- Research Center Eco-Safety
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent.
- Men and women between the ages of 18 and 65 (inclusive).
- Outpatients (including those admitted at home) and inpatients hospitalized for epidemiological reasons, diagnosed with influenza (ICD 10: J10 Influenza caused by an identified influenza virus) of mild to moderate severity.
- Positive result of the rapid enzyme immunoassay test for influenza virus at screening.
- Increase in body temperature in the armpit up to ≥ 38.0 оС at screening (or within 24 hours before screening according to the patient's words).
Presence of at least one of the following symptoms of moderate severity on screening:
headache, weakness/malaise, muscle pain/aches, fever/chills.
- The duration of the disease is no more than 48 hours at the time of screening according to the patient.
- Consent of patients to use adequate methods of contraception throughout the study.
Adequate methods of contraception include the use of:
- oral or transdermal contraceptives;
- a condom or diaphragm (barrier method) with spermicide or
- an intrauterine device.
Exclusion Criteria:
- Pregnant or lactating women or women planning pregnancy during a clinical study; women capable of childbearing (including menopausal women less than 2 years old) who do not use adequate methods of contraception.
- Individual intolerance to the drug AV5080 or its components. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
- Presence of complications of influenza, signs of bacterial infection or severe flu at the time of screening.
- Infectious diseases transferred during the last week before screening
- The need for hospital treatment for influenza, with the exception of hospitalization for epidemiological indications.
- Reception of neuraminidase inhibitors (zanamivir and oseltamivir), immunotropic drugs, systemic glucocorticosteroids, antibacterial drugs of systemic action within 1 month before screening. Taking drugs that prolong the QT interval on an ECG (quinidine, amiodarone, procainamide, phenothiazine derivatives) for 5 half-lives or less before screening.
- A history of influenza vaccination within 3 months prior to screening.
- Chronic diseases of the respiratory system (bronchial asthma, COPD,) in history.
- Persons with metabolic disorders (diabetes mellitus, obesity of 2-3 degrees).
- Hypokalemia at screening (potassium level less than 3.5 mmol/L)
- Persons with chronic kidney disease, chronic liver disease, with certain neurological conditions (including neuromuscular, neurocognitive disorders, epilepsy), hemoglobinopathies or suppressed immune conditions, or due to primary immunosuppressive conditions such as HIV infection, or in connection with secondary immunodeficiency states due to the intake of immunosuppressive medications or malignant neoplasms.
- Significant cardiovascular diseases at present or during 12 months before screening, including: prolongation of the QT interval on ECG more than 450 ms, atrioventricular block, sinus bradycardia, chronic cerebrovascular insufficiency, chronic heart failure class III or IV (according to the classification of the New York Heart Association), severe arrhythmia, requiring treatment with class Ia, Ib, Ic, or III antiarrhythmic drugs, unstable angina pectoris, myocardial infarction, heart and coronary artery surgery, significant heart valve disease, transient ischemic attack or stroke, uncontrolled hypertension with systolic blood pressure> 180 mm Hg ... and diastolic blood pressure> 110 mm Hg, pulmonary embolism or deep vein thrombosis.
- A history of chronic alcoholism, drug addiction or dependence on other chemical compounds.
- Participation in other clinical trials within 3 months prior to screening.
- Inability to read or write; unwillingness to understand and follow research protocol procedures; non-compliance with the regimen of taking medications or performing procedures that, in the opinion of the Investigator, may affect the results of the study or the safety of the patient and prevent the patient from further participation in the study any other comorbid medical or serious mental condition that renders a patient ineligible for participation in a clinical research study, limits the ability to obtain informed consent, or may affect a patient's ability to participate in a study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1.
AV5080 at a daily dose of 160 mg
|
oral hard gelatin capsules
Other Names:
|
Placebo Comparator: Group 2.
Placebo
|
Hard gelatin capsules with a white body
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to symptom resolution
Time Frame: 30 days
|
The resolution of influenza symptoms is confirmed by the absence of symptoms or their reduction to mild severity (0-1 points) and a decrease in body temperature in the armpit to ≤ 37.2 °C for at least 24 hours.
The time to resolve the flu symptoms is the start time of the 24-hour (or longer) interval.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Profile of changes in influenza virus titer versus time (AUC) for 192 hours (in inpatients)
Time Frame: 192 hours
|
192 hours
|
Frequency of symptom resolution within 96 hours of initiation of study therapy
Time Frame: 96 hours
|
96 hours
|
Frequency of elimination of influenza virus before Day 6
Time Frame: 6 Days
|
6 Days
|
The incidence of complications from influenza
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLU-AV5080-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on AV5080
-
ViriomCompletedInfluenzaRussian Federation